Pacific Biosciences (P09) Stock Forecast & Price Target

Compare

2 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

P09 Analyst Ratings

Moderate Buy

2 Buy

3 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Pacific

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

P09 Stock 12 Month Forecast

Average Price Target

€2.12

▲(51.47% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Pacific Biosciences in the last 3 months. The average price target is €2.12 with a high forecast of €2.54 and a low forecast of €1.70. The average price target represents a 51.47% change from the last price of €1.40.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.54475159,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.120626325,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.69650106,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.70</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,1.866519353076923,1.9230387061538463,1.9795580592307693,2.0360774123076926,2.0925967653846156,2.1491161184615386,2.2056354715384616,2.2621548246153846,2.3186741776923077,2.3751935307692307,2.431712883846154,2.488232236923077,{"y":2.54475159,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,1.8338943326923078,1.8577886653846154,1.8816829980769232,1.9055773307692307,1.9294716634615385,1.953365996153846,1.9772603288461539,2.0011546615384614,2.0250489942307692,2.048943326923077,2.0728376596153844,2.096731992307692,{"y":2.120626325,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.81,1.8012693123076924,1.7925386246153847,1.783807936923077,1.7750772492307691,1.7663465615384615,1.7576158738461538,1.7488851861538461,1.7401544984615385,1.7314238107692308,1.722693123076923,1.7139624353846152,1.7052317476923076,{"y":1.69650106,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.504,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.384,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.059,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.944,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.83,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.015,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.078,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.748,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 65, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.95,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 46, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 64, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.81,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€2.54

Average Price Target€2.12

Lowest Price Target€1.70

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Westenberg

Piper Sandler

€1.69

Hold

20.62%

Upside

Reiterated

02/13/26

Pacific Biosciences (PACB) Receives a Hold from Piper Sandler

Kyle Mikson CFA

Canaccord Genuity

€2.53

Buy

80.93%

Upside

Reiterated

02/13/26

Pacific Biosciences (PACB) Gets a Buy from Canaccord Genuity

Luke Sergott

Barclays

€1.69

Hold

20.62%

Upside

Reiterated

02/13/26

Daniel Brennan

TD Cowen

€2.53

Buy

80.93%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Pacific Biosciences (NASDAQ: PACB)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/12/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (NYSE: THC) and Pacific Biosciences (NASDAQ: PACB)

Mason Carrico

Stephens

€1.52→€1.69

Buy

20.62%

Upside

Reiterated

11/10/25

PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

€1.69

Hold

20.62%

Upside

Reiterated

08/10/25

Morgan Stanley Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

Eve Burstein

Bernstein

€1.27→€1.44

Buy

2.53%

Upside

Reiterated

08/08/25

Pacific Biosciences (PACB) Gets a Buy from Bernstein

Tycho Peterson

Jefferies

€2.96→€2.53

Buy

80.93%

Upside

Reiterated

05/09/25

Pacific Biosciences of California (PACB) PT Lowered to $3 at JefferiesJefferies analyst Tycho Peterson lowered the price target on Pacific Biosciences of California (NASDAQ: PACB) to $3.00 (from $3.50) while maintaining a Buy rating.

Sung Ji Nam

Scotiabank

€1.69

Buy

20.62%

Upside

Reiterated

04/10/25

Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)

Ross Osborn

Cantor Fitzgerald

€2.11

Buy

50.78%

Upside

Reiterated

03/18/25

Cantor Fitzgerald reiterates Overweight Rating on Pacific Biosciences of California (PACB)Cantor Fitzgerald analyst Ross Osborn reiterated an Overweight rating and $2.50 price target on Pacific Biosciences of California (NASDAQ: PACB).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Westenberg

Piper Sandler

€1.69

Hold

20.62%

Upside

Reiterated

02/13/26

Pacific Biosciences (PACB) Receives a Hold from Piper Sandler

Kyle Mikson CFA

Canaccord Genuity

€2.53

Buy

80.93%

Upside

Reiterated

02/13/26

Pacific Biosciences (PACB) Gets a Buy from Canaccord Genuity

Luke Sergott

Barclays

€1.69

Hold

20.62%

Upside

Reiterated

02/13/26

Daniel Brennan

TD Cowen

€2.53

Buy

80.93%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Pacific Biosciences (NASDAQ: PACB)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/12/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (NYSE: THC) and Pacific Biosciences (NASDAQ: PACB)

Mason Carrico

Stephens

€1.52→€1.69

Buy

20.62%

Upside

Reiterated

11/10/25

PacBio price target raised to $2 from $1.80 at StephensPacBio price target raised to $2 from $1.80 at Stephens

Yuko Oku

Morgan Stanley

Not Ranked

Morgan Stanley

€1.69

Hold

20.62%

Upside

Reiterated

08/10/25

Morgan Stanley Reaffirms Their Hold Rating on Pacific Biosciences (PACB)

Eve Burstein

Bernstein

€1.27→€1.44

Buy

2.53%

Upside

Reiterated

08/08/25

Pacific Biosciences (PACB) Gets a Buy from Bernstein

Tycho Peterson

Jefferies

€2.96→€2.53

Buy

80.93%

Upside

Reiterated

05/09/25

Sung Ji Nam

Scotiabank

€1.69

Buy

20.62%

Upside

Reiterated

04/10/25

Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)

Ross Osborn

Cantor Fitzgerald

€2.11

Buy

50.78%

Upside

Reiterated

03/18/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pacific Biosciences

3 Months

xxx

Success Rate

10/18 ratings generated profit

Average Return

+3.18%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +3.18% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

8/18 ratings generated profit

Average Return

-12.81%

reiterated a buy rating 10 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -12.81% per trade.

2 Years

xxx

Success Rate

10/18 ratings generated profit

Average Return

-10.54%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of -10.54% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

P09 Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, P09 has received 5 Buy Ratings, 39 Hold Ratings, and 8 Sell Ratings. P09 average Analyst price target in the past 3 months is 2.12.

Each month's total comprises the sum of three months' worth of ratings.

P09 Financial Forecast

P09 Earnings Forecast

Next quarter’s earnings estimate for P09 is -€0.12 with a range of -€0.14 to -€0.10. The previous quarter’s EPS was -€0.11. P09 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year P09 has Performed in-line its overall industry.

P09 Sales Forecast

Next quarter’s sales forecast for P09 is €33.89M with a range of €32.44M to €35.54M. The previous quarter’s sales results were €37.87M. P09 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year P09 has Performed in-line its overall industry.

P09 Stock Forecast FAQ

What is DE:P09’s average 12-month price target, according to analysts?

Based on analyst ratings, Pacific Biosciences’s 12-month average price target is 2.12.

What is DE:P09’s upside potential, based on the analysts’ average price target?

Pacific Biosciences has 51.47% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Pacific Biosciences a Buy, Sell or Hold?

Pacific Biosciences has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.

What is Pacific Biosciences’s share price target?

The average share price target for Pacific Biosciences is 2.12. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €2.54 ,and the lowest forecast is €1.70. The average share price target represents 51.47% Increase from the current price of €1.4.

What do analysts say about Pacific Biosciences?

Pacific Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Pacific Biosciences?

To buy shares of DE:P09, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Pacific Biosciences (P09) Stock Forecast & Price Target

P09 Analyst Ratings

P09 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pacific Biosciences

P09 Analyst Recommendation Trends

P09 Financial Forecast

P09 Earnings Forecast

P09 Sales Forecast

P09 Stock Forecast FAQ

Detailed List of Analyst Forecasts